Trial Summary
What is the purpose of this trial?
This trial is testing a new scan that can quickly show how much radioactive iodine thyroid cancer will absorb. It aims to help doctors plan treatment more effectively without interfering with the therapy. The study focuses on patients with thyroid cancer to improve their treatment outcomes.
Research Team
Ravinder Grewal, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
This trial is for adults over 18 with thyroid cancer of follicular origin, who can sign consent and follow a low iodine diet. They must have normal organ function, not be pregnant or breastfeeding, use contraception if fertile, and have tumors visible on imaging tests. Exclusion includes uncontrolled illness, recent iodinated contrast exposure without clearance, and non-compliance.Inclusion Criteria
I am not pregnant or cannot become pregnant.
My organs and bone marrow are functioning normally.
I am 18 years old or older.
See 5 more
Exclusion Criteria
I had a CT scan with dye within the last 3 months but my body has cleared the iodine.
Pregnant, lactating, or breast feeding women
Unwillingness or inability to comply with study procedures
See 2 more
Treatment Details
Interventions
- 18F-tetrafluoroborate (18F-TFB) (Imaging Agent)
Trial OverviewThe study tests a new PET imaging technique using 18F-Tetrafluoroborate (18F-TFB) to predict radioactive iodine uptake in thyroid cancer more quickly than current methods without affecting therapeutic radioactive iodine uptake.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: PET Imaging With 18F-TFBExperimental Treatment2 Interventions
The intervention is the administration of a single dose of approximately 5-10 mCi 18F-TFB (mass \<= 50 μg) for imaging purposes. This will be followed by a 30 minute dynamic PET/CT study immediately after injection, at 60 minutes (+/- 10 min) and 4 hours (+/- 15 min) post injection. The second and third scan will last up to 30 minutes.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Trials
1,998
Recruited
602,000+
Lisa M. DeAngelis
Memorial Sloan Kettering Cancer Center
Chief Medical Officer since 2021
MD from Columbia University
Selwyn M. Vickers
Memorial Sloan Kettering Cancer Center
Chief Executive Officer since 2022
MD from Johns Hopkins University